Stevens Capital Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $325K | Buy |
+1,774
| New | +$327K | 0.05% | 166 |
|
|
2025
Q4 | – | Sell |
-3,967
| Closed | -$556K | – | 212 |
|
|
2025
Q3 | $556K | Buy |
+3,967
| New | +$536K | 0.07% | 152 |
|
|
2025
Q2 | – | Sell |
-2,884
| Closed | -$395K | – | 246 |
|
|
2025
Q1 | $395K | Buy |
+2,884
| New | +$412K | 0.1% | 147 |
|
|
2024
Q2 | – | Sell |
-9,269
| Closed | -$2M | – | 233 |
|
|
2024
Q1 | $2M | Buy |
9,269
+2,965
| +47% | +$694K | 0.39% | 60 |
|
|
2023
Q4 | $1.63M | Buy |
+6,304
| New | +$1.55M | 0.41% | 51 |
|
|
2023
Q3 | – | Sell |
-2,198
| Closed | -$626K | – | 244 |
|
|
2023
Q2 | $626K | Buy |
+2,198
| New | +$654K | 0.13% | 154 |
|
|
2022
Q2 | – | Sell |
-1,165
| Closed | -$245K | – | 135 |
|
|
2022
Q1 | $245K | Buy |
+1,165
| New | +$253K | 0.05% | 218 |
|
|
2021
Q4 | – | Sell |
-2,794
| Closed | -$791K | – | 239 |
|
|
2021
Q3 | $791K | Buy |
+2,794
| New | +$916K | 0.33% | 66 |
|
|
2021
Q2 | – | Sell |
-1,532
| Closed | -$429K | – | 195 |
|
|
2021
Q1 | $429K | Buy |
+1,532
| New | +$413K | 0.24% | 67 |
|
|
2020
Q1 | – | Sell |
-11,686
| Closed | -$3.47M | – | 44 |
|
|
2019
Q4 | $3.47M | Buy |
+11,686
| New | +$3.24M | 0.32% | 86 |
|
|
2019
Q1 | – | Sell |
-1,207
| Closed | -$363K | – | 686 |
|
|
2018
Q4 | $363K | Buy |
+1,207
| New | +$385K | 0.02% | 540 |
|
|
2018
Q3 | – | Sell |
-24,681
| Closed | -$7.16M | – | 731 |
|
|
2018
Q2 | $7.16M | Buy |
24,681
+14,794
| +150% | +$4.16M | 0.26% | 107 |
|
|
2018
Q1 | $2.71M | Buy |
9,887
+1,163
| +13% | +$361K | 0.1% | 237 |
|
|
2017
Q4 | $2.78M | Sell |
8,724
-4,911
| -36% | -$1.58M | 0.11% | 234 |
|
|
2017
Q3 | $4.27M | Buy |
+13,635
| New | +$4.04M | 0.16% | 177 |
|
|
2017
Q2 | – | Sell |
-20,998
| Closed | -$5.74M | – | 859 |
|
|
2017
Q1 | $5.74M | Sell |
20,998
-10,492
| -33% | -$2.97M | 0.22% | 130 |
|
|
2016
Q4 | $8.93M | Buy |
+31,490
| New | +$9.33M | 0.36% | 76 |
|
|
2016
Q3 | – | Sell |
-9,552
| Closed | -$2.31M | – | 909 |
|
|
2016
Q2 | $2.31M | Buy |
+9,552
| New | +$2.52M | 0.09% | 271 |
|
|
2015
Q3 | – | Sell |
-1,474
| Closed | -$595K | – | 986 |
|
|
2015
Q2 | $595K | Sell |
1,474
-8,114
| -85% | -$3.26M | 0.02% | 570 |
|
|
2015
Q1 | $4.05M | Buy |
9,588
+8,371
| +688% | +$3.3M | 0.14% | 173 |
|
|
2014
Q4 | $413K | Sell |
1,217
-69,454
| -98% | -$22.5M | 0.01% | 628 |
|
|
2014
Q3 | $23.4M | Buy |
+70,671
| New | +$23.3M | 0.7% | 21 |
|
Other funds holding BIIB
VCM
VPM
Stevens Capital Management's BIIB Position: Q1 2026 in Review
Stevens Capital Management opened a new position in Biogen (BIIB) in Q1 2026: 1,774 shares worth $325K. The stake represents 0.05% of the portfolio and ranks #166 among its holdings. This is a return to the name: Stevens Capital Management previously reported a position in BIIB as recently as Q3 2025.
Stevens Capital Management first reported a position in BIIB in Q3 2014 and has held it in 22 quarters since. The position peaked at $23.4M in Q3 2014. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Stevens Capital Management held 1,774 shares of Biogen worth $325K as of Q1 2026.
- Biogen was a new Stevens Capital Management position in Q1 2026.
- Biogen made up 0.05% of Stevens Capital Management's portfolio in Q1 2026, its #166 holding.
- Stevens Capital Management first reported a position in Biogen in Q3 2014 and has held it in 22 quarters since.
- Stevens Capital Management's Biogen position peaked at $23.4M in Q3 2014.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Stevens Capital Management's 13F filing for Q1 2026, filed 11 May 2026.